Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 5—May 2013
Dispatch

Campylobacter coli Outbreak in Men Who Have Sex with Men, Quebec, Canada, 2010–2011

Christiane GaudreauComments to Author , Melissa Helferty, Jean-Loup Sylvestre, Robert Allard, Pierre A. Pilon, Michel Poisson, and Sadjia Bekal
Author affiliations: Centre Hospitalier de l’Université de Montréal–Hôpital Saint-Luc, Montreal, Quebec, Canada (C. Gaudreau); Université de Montréal, Montreal (C. Caudreau, M. Poisson, P.A. Pilon); Agence de la Santé et des Services Sociaux–Santé Publique de Montréal, Montreal (M. Helferty, J.-L. Sylvestre, R. Allard, P.A. Pilon); McGill University, Montreal (R. Allard); Centre Hospitalier de l’Université de Montréal–Hôtel-Dieu, Montreal (M. Poisson); Laboratoire de Santé Publique du Québec/Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Quebec, Canada (S. Bekal); Public Health Agency of Canada, Ottawa, Ontario, Canada (M. Helferty)

Main Article

Table 2

Antimicrobial drug susceptibility results for Campylobacter coli pulsovar 1 isolates from 10 patients, Montreal, Quebec, Canada, 2010–2011*

Antimicrobial agent† MIC (mg/L) Interpretation
Erythromycin 2–4 S
Azithromycin 0.25–0.5 S
Tetracycline 128–256 R
Ciprofloxacin >32 R
Nalidixic acid >256 R
Ampicillin 2–4 S
Gentamicin 0.5–1 S
Cefotaxime >32 R
Imipenem 0.06–0.12 S
Clindamycin 0.25–0.5 S
Chloramphenicol 2–4 S
Tigecycline ≤0.015 NA
β-lactamase‡ Negative –

*S, susceptible; R, resistant; NA, not available; –, not applicable.
†The susceptibility and resistance breakpoints were Clinical and Laboratory Standards Institute (CLSI) Campylobacter breakpoints for erythromycin, tetracycline and ciprofloxacin (10), National Antimicrobial Resistance Monitoring System Campylobacter breakpoints for azithromycin and clindamycin (11), no breakpoints available for tigecycline and CLSI Enterobacteriaceae breakpoints for the 6 other antimicrobial agents (12).
‡β-lactamase susceptibility was determined as described (9).

Main Article

References
  1. Allos  BM, Blaser  MJ. Campylobacter jejuni and related species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 7th ed. Philadelphia: Elsevier Churchill Livingston; 2010. p. 2793–802.
  2. Blaser  MJ, Engberg  J. Clinical aspects of Campylobacter jejuni and Campylobacter coli infections. In: Nachamkin I, Szymanski CM, Blaser MJ, editors. Campylobacter, 3rd ed. Washington (DC): American Society for Microbiology; 2008. p. 99–121.
  3. Fitzgerald  C, Nachamkin  I. Campylobacter and Arcobacter. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, editors. Manual of clinical microbiology, 10th ed. Washington (DC): American Society for Microbiology; 2011. p. 885–99.
  4. Gallay  A, De Valk  H, Cournot  M, Ladeuil  B, Hemery  C, Castor  C, A large multi-pathogen waterbone community outbreak linked to faecal contamination of a groundwater system, France, 2000. Clin Microbiol Infect. 2006;12:561–70. DOIPubMedGoogle Scholar
  5. Wardak  S, Sadkowska-Todys  M. The first report on Campylobacter coli family outbreak detected in Poland in 2006. Euro Surveill. 2008;13:8052 .PubMedGoogle Scholar
  6. Hill  JE, Paccagnella  A, Law  K, Melito  PL, Woodward  DL, Price  L, Identification of Campylobacter spp. and discrimination from Helicobacter and Arcobacter spp. by direct sequencing of PCR-amplified cpn60 sequences and comparison to cpnDB, a chaperonin reference sequence database. J Med Microbiol. 2006;55:393–9. DOIPubMedGoogle Scholar
  7. Hunter  SB, Vauterin  P, Lambert-Fair  MA, Van Duyne  MS, Kubota  K, Graves  L, Establishment of a universal size standard strain for use with the PulseNet standardized pulsed-field gel electrophoresis protocols: converting the national databases to the new size standard. J Clin Microbiol. 2005;43:1045–50. DOIPubMedGoogle Scholar
  8. Gaudreau  C, Girouard  Y, Gilbert  H, Gagnon  J, Bekal  S. Comparison of disk diffusion and agar dilution methods for erythromycin, ciprofloxacin and tetracycline susceptibility testing of Campylobacter coli and for tetracycline for Campylobacter jejuni subsp. jejuni. Antimicrob Agents Chemother. 2008;52:4475–7. DOIPubMedGoogle Scholar
  9. Lachance  N, Gaudreau  C, Lamothe  F, Turgeon  F. Susceptibilities of β-lactamase–positive and –negative strains of Campylobacter coli to β-lactam agents. Antimicrob Agents Chemother. 1993;37:1174–6. DOIPubMedGoogle Scholar
  10. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing for infrequently-isolated or fastidious bacteria: approved guidelines; no. M45–A2, vol. 30, no. 18. Wayne (PA): The Institute; 2010.
  11. Centers for Disease Control and Prevention. 2010. National Antimicrobial Resistance Monitoring System-enteric bacteria (NARMS) 2009 annual report [cited 2011 Jun 29]. http://www.cdc.gov/narms/pdf/NARMSAnnualReport2009_508.pdf.
  12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22th informational supplement; no. M100–S22, vol. 32, no. 3. Wayne (PA): The Institute; 2012.
  13. Gaudreau  C, Michaud  S. Cluster of erythromycin- and ciprofloxacin-resistant Campylobacter jejuni subsp. jejuni from 1999 to 2001 in men who have sex with men, Québec, Canada. Clin Infect Dis. 2003;37:131–6. DOIPubMedGoogle Scholar
  14. Gaudreau  C, Bruneau  A, Ismaïl  J. Outbreak of Shigella flexneri and Shigella sonnei enterocolitis in men who have sex with men, Québec, 1999 to 2001. Can Commun Dis Rep. 2005;31:85–90 .PubMedGoogle Scholar
  15. Gaudreau  C, Ratnayake  R, Pilon  PA, Gagnon  S, Roger  M, Levesque  S. Ciprofloxacin-resistant Shigella sonnei among men who have sex with men, Canada, 2010. Emerg Infect Dis. 2011;17:1747–50. DOIPubMedGoogle Scholar

Main Article

Page created: April 16, 2013
Page updated: April 16, 2013
Page reviewed: April 16, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external